Engineering antibodies for the clinic

Cancer and Metastasis Reviews

Volumn 18, Issue 4, 1999, Pages 411-419

  Holliger, Philipp ^a   Bohlen, Heribert ^b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antibody engineering; Bispecific; Diabody; Humanization; Immunotherapy; Lymphoma

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ANTIBODY; ANTIBODY CONJUGATE; CD20 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD52 ANTIGEN; CHIMERIC ANTIBODY; EDRECOLOMAB; FC RECEPTOR; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; OKT 3; ONCOPROTEIN; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; GENETIC ENGINEERING; HUMAN; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; LYMPHOMA; NEOPLASMS; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; RECOMBINANT FUSION PROTEINS;

EID: 0033499259     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006314421941     Document Type: Article

References (82)

1. 1. Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975
2. 2. Milstein C, Waldmann H: Optimism after much pessimism: what next? Curr Op Immunol 11: 589-591, 1999
3. 3. Winter G, Milstein C: Man-made antibodies. Nature 349: 293-299, 1991
4. 4. Dall'Acqua W, Carter P: Antibody engineering. Curr Op Struc Biol 8: 443-450, 1998
5. 5. Vaughan TJ, Osbourn JK, Tempest PR: Human antibodies by design. Nat Biotech 16: 535-540, 1998
6. 6. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR: Making antibodies by phage display technology. Annu Rev Immunol 12: 433-455, 1994
7. 7. Brüggeman M, Taussig MJ: Production of human antibody repertoires in transgenic mice. Curr Op Biotechnol 8: 503-508, 1997
8. 8. Griffiths AD, Malmqvist M, Marks JD, Bye JM, Embleton MJ, McCafferty J, et al.: Human anti-self antibodies with high specificity from phage display libraries. EMBO J 12: 725-734, 1993
9. 9. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, et al.: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13: 3245-3260, 1994
10. 10. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al.: Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotech 14: 309-314, 1996
11. 11. Sheets MD, Amersdorfer P, Finnern R, Sargent P, Lindqvist E, Schier R, et al.: Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 95: 6157-6162, 1998
12. 12. Hoogenboom HR, de Brune AP, Hufton SE, Hoet RM, Arends JW, Roovers RC: Antibody phage display technology and its applications. Immunotechnology 4: 1-20, 1998
13. 13. Poul MA, Marks JD: Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol 288: 203-211, 1999
14. 14. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature 380: 364-366, 1996
15. 15. Verma R, Boleti E, George AJ: Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Meth 216: 165-181, 1998
16. 16. Skerra A: Bacterial expression of immunoglobulin fragments. Curr Op Immunol 5: 256-262, 1993
17. 17. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, et al.: High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Biotechnology 10: 163-167, 1992
18. 18. Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P: High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 14: 192-196, 1996
19. 19. Tomlinson I, Holliger P: Methods for generating multivalent and bispecific antibody fragments. Meth Enzymol (in press)
20. 20. Knappik A, Plückthun A: Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng 8: 81-89, 1995
21. 21. Wörn A, Plückthun A: Different equilibrium stability behaviour of scFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 38: 8739-8750, 1999
22. 22. Jung S, Plückthun A: Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng 10: 959-966, 1997
23. 23. Coia G, Ayres A, Lilley GG, Hudson PJ, Irving RA: Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. Gene 201: 203-209, 1997
24. 24. Reiter Y, Pastan I: Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Tibtech 16: 513-520, 1998
25. 25. Kreitman RJ: Immunotoxins in cancer therapy. Curr Op Immunol 11: 570-578, 1999
26. 26. Waibel R, Alberto R, Willuda J, Finnern R, Schibli R, Stichelberger A, et al.: Stable one-step technetium-99m labeling of Hs-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotech 17: 897-901, 1999
27. 27. DeNardo SJ, Kroger LA, DeNardo GL: A new era for radiolabeled antibodies in cancer? Curr Op Immunol 11: 563-569, 1999
28. 28. Bagshawe KD, Sharma SK, Burke PJ, Melton RG, Knox RJ: Developments with targeted enzymes in cancer therapy. Curr Op Immunol 11: 579-583, 1999
29. 29. Cao Y, Suresh MR: Bispecific antibodies as novel bioconjugates. Bioconjug Chem 9: 635-644, 1998
30. 30. Segal DM, Weiner GJ, Weiner LM: Bispecific antibodies in cancer therapy. Curr Op Immunol 11: 558-562, 1999
31. 31. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537-540, 1983
32. 32. Karpovsky B, Titus JA, Stephany DA, Segal DM: Production of target-specific effector cells using hetero-crosslinked aggregates containing anti-target cell and anti-Fcγ receptor antibodies. J Exp Med 160: 1686-1701, 1984
33. 33. Staerz UD, Kanagawa O, Bevan MJ: Hybrid antibodies can target sites for attack by T cells. Nature 314: 628-631, 1985
34. 34. Holliger P, Winter G: Engineering bispecific antibodies. Curr Op Biotech 4: 446-449, 1993
35. 35. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al.: An efficient route to human bispecific IgG. Nat Biotech 16: 677-681, 1998
36. 36. Traunecker A, Lanzavecchia A, Karjalainen K: Janusin: new molecular design for bispecific reagents. Int J Cancer Suppl 7: 51-52, 1992
37. 37. Neri D, Momo M, Prospero T, Winter G: High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 246: 367-373, 1995
38. 38. Kurucz I, Titus JA, Jost CR, Jacobus CM, Segal DM: Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria. J Immunol 154: 4576-4582, 1995
39. 39. Gruber M, Schodin BA, Wilson ER, Kranz DM: Efficient tumour cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 152: 5368-5374, 1994
40. 40. De Jonge J, Heirman C, De Veerman M, Van Meirvenne S, Moser M, Leo O, et al.: In vivo retargeting of T-cell effector function by recombinant bispecific single chain Fv (anti-CD3 × anti-idiotype) induces long-term survival in the mutine BCL1 lymphoma model. J Immunol 161: 1454-1461, 1998
41. 41. Holliger P, Prospero T, Winter G: 'Diabodies': small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 6444-6448, 1993
42. 42. McGuinness BT, Walter G, FitzGerald K, Schuler P, Mahoney W, Duncan AR, et al.: Phage diabody repertoires for selection of large numbers of bispecific antibody fragments. Nat Biotech 14: 1149-1154, 1996
43. 43. Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G: Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 9: 299-305, 1996
44. 44. Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR, et al.: Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 76: 232-239, 1998
45. 45. Kipriyanov SM, Moldenhauer G, Strauss G, Little M: Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 77: 763-772, 1998
46. 46. Krebs B, Griffin H, Winter G, Rose-John S: Recombinant human single chain Fv antibodies recognizing human interleukin-6. Specific targeting of cytokine-secreting cells. J Biol Chem 273: 2858-2865, 1998
47. 47. Manzke O, Fitzgerald KJ, Holliger P, Klock J, Span M, Fleischmann B, et al.: CD3 × anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors. Int J Cancer 82: 700-708, 1999
48. 48. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Liu QH, et al.: Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × antiCEA bispecific fusion proteins. Cancer Res 59: 2909-2916, 1999
49. 49. Holliger P, Wing M, Pound JD, Bohlen H, Winter G: Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotech 15: 632-636, 1997
50. 50. Kontermann RE, Wing MG, Winter G: Complement recruitment using bispecific diabodies. Nat Biotech 15: 629-631, 1997
51. 51. Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G: Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 9: 299-305, 1996
52. 52. Pei XY, Holliger P, Murzin AG, Williams RL: The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc Natl Acad Sci USA 94: 9637-9642, 1997
53. 53. Iliades P, Kortt AA, Hudson PJ: Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett 409: 437-441, 1997
54. 54. FitzGerald K, Holliger P, Winter G: Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 10: 1221-1225, 1997
55. 55. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, et al.: Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77: 1405-1412, 1998
56. 56. Wu AM, Wiliams LE, Zieran L, Padma A, Sherman M, Bebb GG, et al.: Anti-carcirnoembryonic antigen (CEA) diabody for rapid tumor imaging. Tumor Targeting 4: 47-54, 1999
57. 57. Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, et al.: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med 2: 979-984, 1996
58. 58. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, et al.: Minibody: a novel engineered anticarcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56: 3055-3061, 1996
59. 59. Ghetie V, Ward ES: FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18: 592-598, 1997
60. 60. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al.: Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotech 15: 637-640, 1997
61. 61. Zuckier LS, Chang CJ, Scharff MD, Morrison SL: Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. Cancer Res 58: 3905-3908, 1998
62. 62. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ: Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotech 17: 780-783, 1999
63. 63. Riechmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 332: 323-327, 1988
64. 64. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, et al.: Remission induction in non-Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH-IH. Lancet 2: 1394-1399, 1988
65. 65. Dyer MJ, Hale G, Hayhoe FG, Waldmann H: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73: 1431-1439, 1989
66. 66. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D: Subcutaneous CAMPATH-IH in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96: 617-619, 1997
67. 67. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-IH Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15: 1567-1574, 1997
68. 68. Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett F, et al.: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15: 2667-2672, 1997
69. 69. Tedder TF, Engel P: CD20: a regulator of cell-cycle progression and B lymphocytes. Immunol Today 15: 450-454, 1994
70. 70. Reff ME. Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445, 1994
71. 71. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 88: 637A, 1996
72. 72. Shan D, Ledbetter JA, Press OW: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652, 1998
73. 73. Demidem A, Hanna N, Hariharan H, Bonavida B: Chimeric anti-CD20 (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B-cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16 and toxins. FASEB J 9: A206, 1995
74. 74. McLaughlin P, White CA, Grillo-LÛpez AJ, Maloney DG: Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology 12 :1763-1769; discussion 1769-1770, 1775-1777,. 1998
75. 75. Czuczman MS, Grillo-LÛpez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276, 1999
76. 76. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles TM, et al.: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2: 457-470, 1996
77. 77. Vose J, Saleh M, Lister A, Rohatiner A, Knox S, Radford J, et al.: Iodine-131 anti-B1 antibody for non-Hodgkin's lymphoma (NHL): overall clinical trial experience [abstract]. Proc Am Soc Clin Oncol 17: 10, 1998
78. 78. Kaminski MS, Gribbin T, Estes J, Ross CW, Regan D, Zasadny K, et al.: I-131 anti-B1 antibody for previously untreated follicular lymphoma (FL): clinical and molecular remissions [abstract]. Proc Am Soc Clin Oncol 17: 2, 1998
79. 79. Kaminski MS, Zelenetz AD, Press O, Saleh M, Leonard J, Fehrenbacher L, et al.: Multicenter phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin's lymphoma (NHL). Blood 92: 1296, 1998
80. 80. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Eng J Med 329: 1219-1224, 1993
81. 81. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al.: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 : 336-340, 1995
82. 82. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, et al.: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525-1533, 1991